@article{3120004,
    title = "Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)",
    author = "Liakos, C.I. and Papadopoulos, D.P. and Sanidas, E.A. and Markou, M.I. and Hatziagelaki, E.E. and Grassos, C.A. and Velliou, M.L. and Barbetseas, J.D.",
    journal = "American Journal of Cardiovascular Drugs",
    year = "2021",
    volume = "21",
    number = "2",
    pages = "123-137",
    publisher = "Adis",
    issn = "1175-3277",
    doi = "10.1007/s40256-020-00423-z",
    keywords = "albiglutide;  alogliptin;  anagliptin;  canagliflozin;  dapagliflozin;  dipeptidyl peptidase IV inhibitor;  dulaglutide;  empagliflozin;  ertugliflozin;  exendin 4;  glucagon like peptide 1 receptor agonist;  ipragliflozin;  linagliptin;  liraglutide;  lixisenatide;  luseogliflozin;  saxagliptin;  semaglutide;  sitagliptin;  sodium glucose cotransporter 2 inhibitor;  teneligliptin;  tofogliflozin;  vildagliptin;  antidiabetic agent;  dipeptidyl peptidase IV inhibitor;  glucagon like peptide 1 receptor, antihypertensive activity;  arterial pressure;  blood pressure monitoring;  cardiovascular effect;  human;  meta analysis (topic);  pathophysiology;  priority journal;  randomized controlled trial (topic);  Review;  animal;  blood pressure;  drug effect;  hypertension;  non insulin dependent diabetes mellitus;  pharmacology, Animals;  Arterial Pressure;  Blood Pressure;  Diabetes Mellitus, Type 2;  Dipeptidyl-Peptidase IV Inhibitors;  Glucagon-Like Peptide-1 Receptor;  Humans;  Hypertension;  Hypoglycemic Agents;  Meta-Analysis as Topic;  Randomized Controlled Trials as Topic;  Sodium-Glucose Transporter 2 Inhibitors",
    abstract = "The prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When DM and hypertension coexist, they constitute a dual cardiovascular threat and should be adequately controlled. Novel antihyperglycemic agents, including sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been used in the treatment of DM. Beyond their glucose-lowering effects, these drugs have shown beneficial pleiotropic cardiovascular effects, including lowering of arterial blood pressure (BP), as acknowledged in the 2019 European Society of Cardiology/European Association for the Study of Diabetes guidelines on diabetes, prediabetes, and cardiovascular diseases. The purpose of this review was to summarize the available information on the BP-reducing effects of these new glucose-lowering drug classes and provide a brief report on underlying pathophysiological mechanisms. We also compare the three drug classes (SGLT-2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors) in terms of their BP-lowering effect and show that the greater BP reduction seems to be achieved with SGLT-2 inhibitors, whereas DPP-4 inhibitors have probably the mildest antihypertensive effect. © 2020, Springer Nature Switzerland AG."
}